Jemperli (Dostarlimab-gxly): An unprecedented cancer trial.
作者信息
Ali Eman, Ellahi Aayat, Adil Mariam, Shaikh Asim, Huda Zunera
机构信息
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Department of Internal Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.
出版信息
Ann Med Surg (Lond). 2022 Jun 25;79:104047. doi: 10.1016/j.amsu.2022.104047. eCollection 2022 Jul.
Abstract
摘要
相似文献
1
Jemperli (Dostarlimab-gxly): An unprecedented cancer trial.杰姆普利（多斯塔利单抗 - gxly）：一项史无前例的癌症试验。
Ann Med Surg (Lond). 2022 Jun 25;79:104047. doi: 10.1016/j.amsu.2022.104047. eCollection 2022 Jul.
2
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.抗 PD-1 单克隆抗体 dostarlimab 治疗复发性或晚期错配修复缺陷型子宫内膜癌患者的临床活性和安全性。
Future Oncol. 2021 Oct 1;17(29):3781-3785. doi: 10.2217/fon-2021-0598. Epub 2021 Aug 24.
3
Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models.在体外细胞检测和体内动物模型中，dostarlimab（一种具有强大增强免疫功能活性的抗 PD-1 抗体）具有强大的临床前特征。
MAbs. 2021 Jan-Dec;13(1):1954136. doi: 10.1080/19420862.2021.1954136.
4
Dostarlimab (Jemperli) for endometrial cancer.多斯塔利单抗（Jemperli）用于治疗子宫内膜癌。
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e64-e65. doi: 10.58347/tml.2023.1673h.
5
In brief: A new endometrial cancer indication for dostarlimab (Jemperli).简而言之：多斯塔利单抗（Jemperli）有了新的子宫内膜癌适应症。
Med Lett Drugs Ther. 2023 Aug 21;65(1683):e138. doi: 10.58347/tml.2023.1683f.
6
Dostarlimab-gxly.多斯塔利单抗-gxly
Am J Health Syst Pharm. 2021 Aug 30;78(17):1537-1540. doi: 10.1093/ajhp/zxab229.
7
New Drug Update: Dostarlimab, Loncastuximab Tesirine, and Aducanumab.新药更新：多斯塔利单抗、朗斯妥昔单抗替西瑞林和阿杜卡单抗。
Sr Care Pharm. 2022 Jan 1;37(1):9-16. doi: 10.4140/TCP.n.2022.9.
8
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.多塔利单抗治疗晚期或复发性 DNA 错配修复缺陷/微卫星不稳定高（dMMR/MSI-H）或 proficient/stable（MMRp/MSS）子宫内膜癌患者的安全性和抗肿瘤活性：GARNET 研究的初步结果，一项 I 期单臂研究。
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003777.
9
An Integrated Analysis of Dostarlimab Immunogenicity.多塔利单抗免疫原性的综合分析。
AAPS J. 2021 Jul 29;23(5):96. doi: 10.1208/s12248-021-00624-7.
10
Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy.度伐利尤单抗（dostarlimab）阻断PD-1的分子基础，度伐利尤单抗是美国食品药品监督管理局（FDA）批准用于癌症免疫治疗的抗体。
Biochem Biophys Res Commun. 2022 Apr 9;599:31-37. doi: 10.1016/j.bbrc.2022.02.026. Epub 2022 Feb 9.
引用本文的文献
1
Precision Medicine in High-Grade Serous Ovarian Cancer: Targeted Therapies and the Challenge of Chemoresistance.高级别浆液性卵巢癌中的精准医学：靶向治疗与化疗耐药挑战
Int J Mol Sci. 2025 Mar 12;26(6):2545. doi: 10.3390/ijms26062545.
2
Nanomedicines in diagnosis and treatment of prostate cancers: an updated review.纳米药物在前列腺癌诊断与治疗中的应用：最新综述
Front Bioeng Biotechnol. 2024 Aug 21;12:1444201. doi: 10.3389/fbioe.2024.1444201. eCollection 2024.
本文引用的文献
1
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.PD-1 阻断在错配修复缺陷、局部晚期直肠癌中的应用。
N Engl J Med. 2022 Jun 23;386(25):2363-2376. doi: 10.1056/NEJMoa2201445. Epub 2022 Jun 5.
2
Association of GSTM1 and GSTT1 genes insertion/deletion polymorphism with colorectal cancer risk: A case-control study of Khyber Pakhtunkhwa population, Pakistan.谷胱甘肽硫转移酶 M1 和 T1 基因插入/缺失多态性与结直肠癌风险的关联：巴基斯坦开伯尔-普赫图赫瓦省人群的病例对照研究。
J Pak Med Assoc. 2022 Mar;72(3):457-463. doi: 10.47391/JPMA.1393.
3
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.多塔利单抗治疗晚期或复发性 DNA 错配修复缺陷/微卫星不稳定高（dMMR/MSI-H）或 proficient/stable（MMRp/MSS）子宫内膜癌患者的安全性和抗肿瘤活性：GARNET 研究的初步结果，一项 I 期单臂研究。
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003777.
4
Dostarlimab: First Approval.多斯塔利单抗：首次获批。
Drugs. 2021 Jul;81(10):1213-1219. doi: 10.1007/s40265-021-01539-5.
5
Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial.抗程序性死亡 1 单克隆抗体 dostarlimab 治疗复发性或晚期错配修复缺陷型子宫内膜癌患者的临床活性和安全性：一项非随机 1 期临床试验。
JAMA Oncol. 2020 Nov 1;6(11):1766-1772. doi: 10.1001/jamaoncol.2020.4515.
Zotero 插件